Trial Profile
Comparing the efficacy and safety of Nivolumab in the HIV-infected and HIV-uninfected veteran populations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Squamous cell cancer
- Focus Therapeutic Use
- 20 Apr 2018 New trial record
- 18 Apr 2018 Results presented at the 109th Annual Meeting of the American Association for Cancer Research.